

For Immediate Release

Q3 Net Profit at Rs 86 cr, Net Revenues at Rs 776 cr

Vadodara January 25th, 2017

Alembic Pharmaceuticals Limited reported its consolidated financial results for the third quarter ending 31st December 2016.

Financial Highlights

- Net Sales for the quarter were Rs 776 crores as against Rs 930 crores last year
- Net Profit for the quarter was Rs 86 crores as against Rs 269 crores last year
- The previous period includes revenues and profits from the Aripiprazole generic launch in the US market, which had limited competition. Hence the numbers are strictly not comparable.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “Our base business in the US market is doing well. We will continue to invest in R&D for the future growth and have spent Rs 117 crores in the quarter, which is approximately 15% of revenue on R&D, this is up from Rs 70 crores last year”

Operational Highlights for the quarter

International Business

- International formulation business at Rs. 303 crores as against Rs 521 crores last year
- 3 ANDA final approvals were received, Cumulative ANDA approvals at 52
- 4 ANDA applications were filed, Cumulative ANDA filings at 85

India Branded Formulations

- India Branded formulations at Rs. 294 crores for Q3 FY 2016-17 as against Rs 288 crores during the same period in last year



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837

Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q3 FY17	Q3 FY16	YTD DEC FY17	YTD DEC FY16
Formulation				
International	303	521	963	1272
India Branded	294	288	910	834
India Generics	13	20	59	73
API	166	101	459	358
Total	776	930	2391	2537

The Profit break-up is as under:

(Rs in Crores)

Particulars	Q3 FY17	Q3 FY16	YTD DEC FY17	YTD DEC FY16
EBITDA Post R&D	145	384	480	864
<i>EBITDA Post R&D %</i>	<i>19%</i>	<i>41%</i>	<i>20%</i>	<i>34%</i>
EBITDA Pre R&D	262	454	785	1060
<i>EBITDA Pre R&D %</i>	<i>34%</i>	<i>49%</i>	<i>33%</i>	<i>42%</i>
Profit Before Tax	124	364	417	817
Net Profit after Tax	86	269	307	628



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837

Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 – 306 11681	Phone: +91 265 – 3007630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837

Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123